Werner Koopman, theme Metabolic Diseases, received 250K Euro as a member of the CureMILS consortium. The latter is funded by the European Joint Programme on Rare Diseases (EJP-RD), which brings together over 130 institutions from 35 countries and focuses on pre-clinical research to develop effective therapies for rare diseases.
The project will run for three years, receiving a total of 2.4 million Euro in funding, and will apply a cell-based reprogramming strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh Syndrome.
CureMILS involves eight academic partners from Germany (Heinrich Heine University, Duesseldorf; Fraunhofer IME, Hamburg), Austria (Innsbruck University), The Netherlands (Radboudumc), Finland (University of Helsinki), Poland (Institute of Genetics and Animal Biotechnology, Jastrzebiec), Italy (Verona University) and Luxemburg (University of Luxembourg). Other participants include various collaborators (Germany, Austria and Italy) and a patient organization (International Mito Patients; IMP).
At Radboudumc, CureMILS will be carried out in a collaborative effort between the groups of Werner Koopman and Nael Nadif Kasri.
Related news items
Joint research in regional hospitals New research projects from promotion fund22 November 2022
Four research projects have been honored in the promotion fund of the Radboudumc and four regional hospitals. The research projects, which are a collaboration between CWZ, Jeroen Bosch Hospital, Rijnstate, Sint Maartenskliniek and the Radboudumc will receive a contribution of 240,000 euros.read more